Search hospitals > Virginia > Richmond
Virginia Cancer Institute
Claim this profileRichmond, Virginia 23230
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
174 reported clinical trials
20 medical researchers
Summary
Virginia Cancer Institute is a medical facility located in Richmond, Virginia. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Virginia Cancer Institute is involved with conducting 174 clinical trials across 167 conditions. There are 20 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Khalid Matin.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Andrew Poklepovic, MDVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Tumors
33 reported clinical trials
82 drugs studied
Sarah W. Gordon, DOVirginia Commonwealth University/Massey Cancer Center7 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
54 drugs studied
Leslie Randall, MDVCU Massey Cancer Center1 year of reported clinical research
Studies Ovarian Cancer
Studies Cancer
18 reported clinical trials
33 drugs studied
Khalid MatinVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
13 reported clinical trials
29 drugs studied
Clinical Trials running at Virginia Cancer Institute
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Colorectal Cancer
Multiple Myeloma
Bile Duct Cancer
Squamous Cell Carcinoma
Rectal Cancer
Solid Tumors
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Gedatolisib + Fulvestrant +/- Palbociclib
for Advanced Breast Cancer
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Recruiting2 awards Phase 311 criteria
sac-TMT + Pembrolizumab
for Breast Cancer
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (sac-TMT; MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sac-TMT plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sac-TMT plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Virginia Cancer Institute?
Virginia Cancer Institute is a medical facility located in Richmond, Virginia. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Virginia Cancer Institute is involved with conducting 174 clinical trials across 167 conditions. There are 20 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Khalid Matin.